 |
|
|
| |
RETREATMENT WITH TELAPREVIR + PEGINTERFERON/RIBAVIRIN AFTER A SHORT EXPOSURE TO TELAPREVIR IN PHASE 1 STUDIES: INTERIM RESULTS FROM A PHASE 3B ROLLOVER TRIAL (C219)
|
| |
| |
Reported by Jules Levin
Presented at Asian Pacific Association for the Study of the Liver (APASL), Taipei, Taiwan, February 16-19, 2012
Sandra De Meyer1*, Christoph Sarrazin2, Henk W. Reesink3, Stefan Zeuzem2, Christine J. Weegink3, Don Luo4, James Witek4, Tara L. Kieffer5, Inge Dierynck1, Gaston Picchio4
Janssen Infectious Diseases BVBA, Beerse, Belgium. 2. Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany. 3. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands. 4. Janssen Research & Development, Titusville, NJ, United States. 5. Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States.
*Address correspondence to: Sandra De Meyer, PhD
Janssen Infectious Diseases BVBA,
Turnhoutseweg 30
B2340 Beerse, Belgium
sdmeyer@its.jnj.com
from Jules: data from this study was I recall presented at AASLD Nov 2012, I'm not sure if new data was included here but this data is encouraging although not complete proof regarding the affect & outcome of protease resistance that emerges during initial therapy and whether it is really new resistance or whether it remains archived or disappears over time. So, can HCV protease inhibitors be re-used in retreating patients who did not achieve an SVR with triple therapy, well these data are encouraging, suggest that perhaps there might be benefit. As said in Conclusions below by authors 'further analyses will determine the impact of prior TVR exposure on re-treatment outcome. Studies have found drug resistance appears to disappear after 8-30 months off therapy and in this study Illumina Deep 'population' Sequencing was used. In this study [see full poster report attached] study participants were off TVR for 4.9 to 6 years.
|
| |
|
|
|
|
|
